by admin | 16th March 2023 | News
OKYO Pharma Limited (“OKYO” or the “Company”) Closing of Global Private Placement London, March 16, 2023 – OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat... by admin | 28th February 2023 | News
OKYO Pharma Limited(“OKYO”, “OKYO Pharma” or the “Company”) OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease London and New York, NY, February 28, 2023 – OKYO Pharma Limited (LSE:... by admin | 23rd February 2023 | News
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to its Scientific Advisory Board World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma London and New York, NY, February... by admin | 21st February 2023 | News
OKYO Pharma Limited(“OKYO”, “OKYO Pharma” or the “Company”) OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023. London and New York, NY, February 21, 2023 – OKYO Pharma Limited (LSE: OKYO; NASDAQ:...